UA93148C2 - Дозированная форма тароликмуса модифицированного высвобождения - Google Patents
Дозированная форма тароликмуса модифицированного высвобожденияInfo
- Publication number
- UA93148C2 UA93148C2 UAA200909959A UAA200909959A UA93148C2 UA 93148 C2 UA93148 C2 UA 93148C2 UA A200909959 A UAA200909959 A UA A200909959A UA A200909959 A UAA200909959 A UA A200909959A UA 93148 C2 UA93148 C2 UA 93148C2
- Authority
- UA
- Ukraine
- Prior art keywords
- tacrolimus
- amount
- dosage form
- release dosage
- hours
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Transplantation (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Изобретение касается дозированной формы такролимуса модифицированного высвобождения, которая включает по крайней мере две дозированные единицы, причем по крайней мере одна дозированная единица является дозированной единицей немедленного высвобождения, которая включает первое количество такролимуса в количестве от 10 % (масса/масса) до 70 % (масса/масса) от общего количества такролимусу и один или несколько наполнителей, и по крайней мере вторая дозированная единица является дозированной единицей отсроченного высвобождения, которое включает второе количество такролимуса в количестве от 30 % (масса/масса) до 90 % (масса/масса) от общего количества такролимуса, материал отсроченного высвобождения и один или несколько наполнителей. Дозированная форма согласно изобретению демонстрирует улучшенну�
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN583MU2007 | 2007-03-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
UA93148C2 true UA93148C2 (ru) | 2011-01-10 |
Family
ID=39642954
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UAA200909959A UA93148C2 (ru) | 2007-03-29 | 2008-03-25 | Дозированная форма тароликмуса модифицированного высвобождения |
Country Status (15)
Country | Link |
---|---|
US (1) | US20100086592A1 (ru) |
EP (1) | EP1974722A3 (ru) |
JP (1) | JP2010522742A (ru) |
KR (1) | KR20100014629A (ru) |
CN (1) | CN101652141A (ru) |
AU (1) | AU2008288105A1 (ru) |
BR (1) | BRPI0809563A2 (ru) |
CA (1) | CA2680680A1 (ru) |
CL (1) | CL2008000914A1 (ru) |
EA (1) | EA200970897A1 (ru) |
IL (1) | IL201008A0 (ru) |
MX (1) | MX2009010556A (ru) |
NZ (1) | NZ579811A (ru) |
UA (1) | UA93148C2 (ru) |
WO (1) | WO2009022354A2 (ru) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE033011T2 (hu) | 2007-05-30 | 2017-11-28 | Veloxis Pharmaceuticals As | Takrolimuszt tartalmazó napi egyszeri orális dózisforma |
US12083103B2 (en) | 2007-05-30 | 2024-09-10 | Veloxis Pharmaceuticals, Inc. | Tacrolimus for improved treatment of transplant patients |
CN102119027A (zh) * | 2008-06-26 | 2011-07-06 | 麦克内尔-Ppc股份有限公司 | 含有药物活性剂的包衣颗粒 |
KR101174183B1 (ko) | 2008-11-28 | 2012-08-16 | 주식회사 삼양바이오팜 | 생체이용률이 향상된 타크로리무스 제제 및 상기 제제의 제조방법 |
SG174658A1 (en) | 2010-04-01 | 2011-10-28 | Theravida Inc | Pharmaceutical formulations for the treatment of overactive bladder |
KR101873075B1 (ko) * | 2010-08-18 | 2018-06-29 | 에보니크 룀 게엠베하 | 하나 이상의 알긴산 염을 포함하는 위 내성 제약 또는 건강기능식품 제제 |
KR101243938B1 (ko) * | 2010-10-19 | 2013-03-19 | 이희엽 | 타크롤리무스를 유효성분으로 함유하는 서방형 펠렛 |
CN103813792B (zh) | 2011-05-10 | 2015-11-25 | 塞拉维达公司 | 用于治疗膀胱过度活动症的索利那新和唾液刺激剂的组合 |
DE102011053068A1 (de) * | 2011-08-29 | 2013-02-28 | Hennig Arzneimittel Gmbh & Co. Kg | Darreichungsform mit stabilisierten Wirkstoffpartikeln |
KR20130028824A (ko) * | 2011-09-09 | 2013-03-20 | 주식회사 삼양바이오팜 | 타크로리무스를 포함하는 고체 분산체 및 이의 제조방법 |
US10639283B2 (en) | 2012-08-27 | 2020-05-05 | Evonik Operations Gmbh | Gastric resistant pharmaceutical or nutraceutical composition with resistance against the influence of ethanol |
WO2016025533A2 (en) * | 2014-08-11 | 2016-02-18 | Whitehead Institute For Biomedical Research | Compositions and methods for treating synucleinopathies |
CN104473907A (zh) * | 2014-12-25 | 2015-04-01 | 北京华禧联合科技发展有限公司 | 一种他克莫司的口服缓释制剂 |
BR112017016657A2 (pt) | 2015-02-20 | 2018-04-10 | Cytec Ind Inc | composições de sulfossuccinato de dialquila, método de feitura, e método de uso |
WO2017127073A1 (en) | 2016-01-20 | 2017-07-27 | Theravida, Inc. | Methods and compositions for treating hyperhidrosis |
CA3105214A1 (en) | 2018-06-29 | 2020-01-02 | Incyte Corporation | Formulations of an axl/mer inhibitor |
US20200038560A1 (en) * | 2018-07-31 | 2020-02-06 | Cook Medical Technologies Llc | Limus coatings and methods of use thereof |
CA3063417C (en) * | 2018-12-04 | 2023-01-03 | Leon-Nanodrugs Gmbh | Nanoparticles comprising tacrolimus |
GR1009790B (el) * | 2019-03-20 | 2020-08-03 | Φαρματεν Α.Β.Ε.Ε. | Σκευασμα παρατεταμενης αποδεσμευσης που περιλαμβανει τακρολιμους |
US10752642B1 (en) | 2019-04-30 | 2020-08-25 | George Mason University | Macrocyclic lactones |
CN112569187B (zh) * | 2019-09-27 | 2022-04-12 | 武汉科福新药有限责任公司 | 一种他克莫司纳米眼用乳及其制备方法 |
US11666560B2 (en) | 2020-09-24 | 2023-06-06 | George Mason University | Anti-fibrotic agent |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI1064942T1 (en) | 1998-03-26 | 2004-12-31 | Fujisawa Pharmaceutical Co., Ltd. | Sustained release preparation of a macrolide |
US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US20030180352A1 (en) * | 1999-11-23 | 2003-09-25 | Patel Mahesh V. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
EP1663216B1 (en) * | 2003-08-29 | 2011-11-02 | Veloxis Pharmaceuticals A/S | Modified release compositions comprising tacrolimus |
CN101869561A (zh) | 2003-08-29 | 2010-10-27 | 生命周期药物公司 | 含有他克莫司的改良释放组合物 |
DE10353196A1 (de) * | 2003-11-13 | 2005-06-16 | Röhm GmbH & Co. KG | Mehrschichtige Arzneiform mit einer die Abgabe einer modulatorischen Substanz beeinflussenden Matrix |
US7470435B2 (en) * | 2003-11-17 | 2008-12-30 | Andrx Pharmaceuticals, Llc | Extended release venlafaxine formulation |
US20050181050A1 (en) * | 2004-01-28 | 2005-08-18 | Collegium Pharmaceutical, Inc. | Dosage forms using drug-loaded ion exchange resins |
JP2008524239A (ja) * | 2004-12-15 | 2008-07-10 | エラン ファーマ インターナショナル リミティド | ナノ粒子のタクロリムス製剤 |
-
2008
- 2008-03-25 CA CA002680680A patent/CA2680680A1/en not_active Abandoned
- 2008-03-25 NZ NZ579811A patent/NZ579811A/en not_active IP Right Cessation
- 2008-03-25 UA UAA200909959A patent/UA93148C2/ru unknown
- 2008-03-25 CN CN200880010774A patent/CN101652141A/zh active Pending
- 2008-03-25 AU AU2008288105A patent/AU2008288105A1/en not_active Abandoned
- 2008-03-25 WO PCT/IN2008/000179 patent/WO2009022354A2/en active Application Filing
- 2008-03-25 JP JP2010500442A patent/JP2010522742A/ja not_active Withdrawn
- 2008-03-25 EA EA200970897A patent/EA200970897A1/ru unknown
- 2008-03-25 KR KR1020097020203A patent/KR20100014629A/ko not_active Application Discontinuation
- 2008-03-25 BR BRPI0809563-9A2A patent/BRPI0809563A2/pt not_active IP Right Cessation
- 2008-03-25 MX MX2009010556A patent/MX2009010556A/es not_active Application Discontinuation
- 2008-03-25 US US12/530,011 patent/US20100086592A1/en not_active Abandoned
- 2008-03-28 EP EP08006027A patent/EP1974722A3/en not_active Withdrawn
- 2008-03-28 CL CL200800914A patent/CL2008000914A1/es unknown
-
2009
- 2009-09-17 IL IL201008A patent/IL201008A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA2680680A1 (en) | 2009-02-19 |
AU2008288105A1 (en) | 2009-02-19 |
IL201008A0 (en) | 2010-05-17 |
EP1974722A3 (en) | 2009-03-04 |
WO2009022354A3 (en) | 2009-04-09 |
JP2010522742A (ja) | 2010-07-08 |
MX2009010556A (es) | 2009-10-22 |
BRPI0809563A2 (pt) | 2014-09-16 |
CL2008000914A1 (es) | 2008-07-18 |
WO2009022354A2 (en) | 2009-02-19 |
NZ579811A (en) | 2012-02-24 |
EA200970897A1 (ru) | 2010-04-30 |
KR20100014629A (ko) | 2010-02-10 |
US20100086592A1 (en) | 2010-04-08 |
CN101652141A (zh) | 2010-02-17 |
EP1974722A2 (en) | 2008-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2009010556A (es) | Formas de dosificacion modificada de tacrolimus. | |
GEP20146166B (en) | Pharmaceutical composition | |
MY159630A (en) | Pharmaceutical composition comprising linagliptin and optionally a sglt2 inhibitor, and uses thereof | |
TN2012000152A1 (en) | Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes | |
WO2007090882A3 (en) | Pharmaceutical extended release compositions comprising pramipexole | |
EP2415749A4 (en) | NEW SALVIANOLIC ACID CONNECTION L, PREPARATION METHOD AND USE | |
MX2012007375A (es) | 3-ceto-n-propargil 1-aminoindano. | |
TN2012000248A1 (en) | Novel spiropiperidine compounds | |
TW200730200A (en) | Method for the preparation of a wet granulated drug product | |
TW200745149A (en) | Crystalline form of 1'-(1-methylethyl)-4'-[(2-fluoro-4-methoxyphenyl)methyl]-5'-methyl-1H-pyrazol-3'-O-β-D-glucopyranoside, a method for its preparation and the use thereof for preparing medicaments | |
WO2012021629A3 (en) | Novel d3 dopamine receptor agonists to treat dyskinesia in parkinson's disease | |
MY175800A (en) | Combination treatment of cancer | |
MX2011012122A (es) | Derivados de tiofeno. | |
HK1136828A1 (en) | Spirocyclic cyclohexane derivatives | |
GEP20135744B (en) | Quinuclidine carbonate derivatives and medicinal compositions containing the same | |
GEP20135806B (en) | Lactams as beta secretase inhibitors | |
WO2013012485A3 (en) | Novel crystalline forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione | |
EA201171271A1 (ru) | Фармацевтическая композиция в форме частиц с опиоидом и антагонистом опиоида | |
WO2012052169A3 (de) | Partikelförmige pharmazeutische zusammensetzung mit einem opioid und einem opioid-antagonisten | |
WO2013128379A3 (en) | Crystalline polymorphic forms of linagliptin | |
WO2010044097A3 (en) | Novel dosage form of paliperidone and process for preparing the same | |
TW200833371A (en) | Process for solid formulations | |
MA34580B1 (fr) | Valsartan hautement cristallin | |
WO2012151464A3 (en) | Use of radiographic contrast agents for detecting dental caries | |
MY179041A (en) | Crystalline forms of a 3-carboxypropyl-aminotetralin compound |